Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Comparison of Opioid and Duloxetine for Postoperative Pain Control After Total Knee Arthroplasty: RCT

19 de enero de 2021 actualizado por: Yong In, The Catholic University of Korea

Comparison of Opioid and Duloxetine for Postoperative Pain Control After Total Knee Arthroplasty: Randomized Controlled Trial

Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) has recently been reported to be effective in controlling pain in persistent chronic pain caused by joint surgery and arthritis. However, opioids are important drugs that still play a pivotal role in pain control after surgery. In this study, we want to investigate the difference of the result among patients who undego total knee arthroplasty (TKA), of the result of pain control after TKA from SNRI administration of duloxetine and opioid in two groups. We designed a randomized controlled study (RCT) for the effect of post-TKA pain control to determine whether SNRI is effective in controlling post-TKA pain compared to Opioid, and whether there is a difference in side effects.

Descripción general del estudio

Estado

Desconocido

Intervención / Tratamiento

Descripción detallada

For patients undergoing TKA for osteoarthritis of the knee joint, pain control will be performed using the same pain control technique (pain control using NSAID) until discharge (1 week after surgery) after surgery. By evaluating the Visual Analogue Scale (VAS), which is known as the patient's pain criterion, the study will be conducted only on patients whose score is more severe than 4 points. Among these subjects, only patients who agreed to the study will be assigned to the group taking duloxetine and the group taking opioids with the same probability according to the randomization table for one week after surgery, that is, upon discharge. In our hospital, almost all patients with total knee arthroplasty are discharged one week after surgery, except for special cases such as morbidity of systemic diseases such as cardiopulmonary dysfunction or acute infection after surgery.

Among the co-researchers, one researcher who is in charge of only patient assignment is selected, and the person in charge creates a randomization table through computer generated randomization. During the assignment process, the assignee will not know in advance the next assignment group, and the randomization table is kept in secret. The assignee does not intervene in any other process of this study, and participates only in the task of selecting the assigned group using random checks. The evaluation is evaluated by an evaluator who is not aware of the patient allocation according to the randomization table among researchers participating in the clinical study. Such a study plan will be fully explained to the patient in the process of seeking consent for the study before discharge, as it is recorded in detail in the subject description, and only patients who have obtained this consent will be the subject of the study.

This criterion is established because both duloxetine and opioid are not used for all patients after surgery, but for additional pain control after surgery. Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. In general, if duloxetine is not taken for more than 10 weeks, the frequency of discontinuation syndrome that can occur after discontinuation is remarkably low, so the administration period of 6 weeks was set as the administration period. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups.

As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.

Before surgery, 1 week after surgery, 2 weeks, 6 weeks, 3 months, 6 months, 1 year The degree of pain will be measured using the VAS pain scale, WOMAC pain scale, Brief pain inventory (BPI), Intermittent and Constant Osteoarthritis The pain (ICOAP) score is used to measure additional pain scales in various ways. In addition, SF-36 will be measured before surgery, at 6 weeks, 3 months, 6 months, and 1 year after surgery.

Tipo de estudio

Intervencionista

Inscripción (Anticipado)

160

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

19 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Adults over age 19
  • Patients undergoing total knee arthroplasty for osteoarthritis of the knee joint
  • Patients with a pain VAS scale of 4 or more out of 10 after TKA with a pain in the knee joint during daily activities on flat ground
  • Patients who are willing or able to follow doctor's instructions, including joint exercises
  • Patients not participating in other clinical trials
  • Patients who have received sufficient explanation for this clinical trial and agreed to participate

Exclusion Criteria:

  • Patients with secondary knee osteoarthritis
  • Patients with hypersensitivity reactions and serious side effects to duloxetine or opioid
  • Patients with inflammatory arthritis or crystalline arthritis
  • Local infection to the lower extremities of the pain area, sepsis, or previous neurological abnormalities.
  • Patients who underwent meniscus surgery on the knee joint in the painful area
  • If there is construction or deformation of the knee joint in the pain area
  • Patients with serious heart-related diseases such as cardiac arrest, a history of cerebral infarction, or ischemic heart disease
  • Patients with high blood pressure with poor blood pressure control (Systolic Blood Pressure of> 150 mmHg or Diastolic Blood Pressure> 95 mmHg)
  • Patients with abnormal liver function (ALT)> 2.0 times the upper limit of normal (ULN) or blood urea nitrogen (BUN) or serum creatinine> 2.0 times ULN)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Experimental: Duloxetine group
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine or opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
Comparador activo: Active comparator: Opioid group
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine or opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Pain Visual Analogue Scale
Periodo de tiempo: changes of the VAS score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
score ranges 0 to 10, higher score means more painful
changes of the VAS score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
Brief pain inventory (BPI)
Periodo de tiempo: changes of the BPI score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
includes 7 categories. each category score ranges 0 to 10, higher score means more painful
changes of the BPI score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
WOMAC(Western Ontario and McMaster University Arthritis Index ) pain scale
Periodo de tiempo: changes of the WOMAC score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). higher score means more painful.
changes of the WOMAC score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
Intermittent and Constant Osteoarthritis pain (ICOAP) score
Periodo de tiempo: changes of the ICOAP score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
11-item tool that assess pain at knee joint. The 11 items are scored froma 0 to 4 with 0 being no pain and 4 being extreme pain
changes of the ICOAP score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
SF-36(Short Form Health Survey - 36) score
Periodo de tiempo: changes of the SF-36 score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability
changes of the SF-36 score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
Range of Motion
Periodo de tiempo: The day before TKA operation, postoperative 1, 2, 6, 12, 24 weeks and 1 year
The day before TKA operation, postoperative 1, 2, 6, 12, 24 weeks and 1 year

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Anticipado)

1 de enero de 2021

Finalización primaria (Anticipado)

1 de diciembre de 2022

Finalización del estudio (Anticipado)

1 de diciembre de 2022

Fechas de registro del estudio

Enviado por primera vez

6 de enero de 2021

Primero enviado que cumplió con los criterios de control de calidad

19 de enero de 2021

Publicado por primera vez (Actual)

22 de enero de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de enero de 2021

Última actualización enviada que cumplió con los criterios de control de calidad

19 de enero de 2021

Última verificación

1 de enero de 2021

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Duloxetine vs. Opioid

3
Suscribir